Home
NewsNewsMemphasys Felix Qatar IVF orders secure Hamad Medical Corporation as a reference customer, driving robust cartridge demand, accelerating widespread IVF adoption across the MENA region, and establishing crucial clinical credibility for future expansion.
Memphasys Felix Qatar IVF orders entered a commercial execution phase after Hamad Medical Corporation (HMC) began routine clinical purchasing of Felix™ cartridges in Qatar. HMC, the country’s largest public healthcare provider and leading IVF service, is now ordering approximately 100 cartridges per month, supporting close to 1,500 IVF cycles annually and creating a recurring institutional demand profile.
The agreement marks Memphasys’ first large-scale institutional customer in the Middle East and North Africa and follows CE Mark approval, which allows Felix™ to be used immediately across Qatar and other CE-recognised MENA markets. The deployment is being executed under Memphasys’ go-direct commercial strategy with distribution partner International Technical Legacy.
HMC’s projected annual usage of roughly 1,200 cartridges represents almost half of International Technical Legacy’s minimum annual commitment of 2,500 cartridges, significantly de-risking contracted volumes. This single institutional adoption also establishes a high-credibility reference point for Memphasys Felix Qatar IVF orders as the company targets broader uptake across the region’s estimated 350 IVF clinics.
Felix™ is positioned as an alternative to centrifugation-based sperm preparation, which can expose sperm cells to mechanical stress and DNA damage. The system uses a patented bioseparation process combining electrophoresis and size-exclusion membranes to isolate viable sperm with reduced cellular stress, faster laboratory workflows and more standardised results across operators.
Outside of Qatar, Memphasys has also received a follow-on order of 200 cartridges from International Technical Legacy (ITL), representing demand from clinics across the UAE and neighbouring regions. Memphasys is in late-stage commercial discussions with clinics in five other countries, looking to expand into those markets in the short-term.
Egypt will be another focus market for Memphasys expansion, with demand for IVF therapies expected to reach over USD 500 million. To continue supporting growth in the region, Memphasys’ A/Prof Hassan Bakos, Director of Clinical Partnerships and Growth, will undertake his second partner-funded visit to the region. He will be working with HMC to optimise usage, onboard clinics rapidly and meet with clinicians at a large ART conference taking place in Egypt.
Together, the HMC deployment and follow-on regional orders demonstrate that Felix™ is transitioning from evaluation to routine clinical use. The cartridge-based consumable model supports recurring revenue, while institutional adoption provides validation that extends beyond a single customer win.
A federal judge has approved a class-action settlement requiring Aetna to extend equal Fertility Coverage for Same-Sex Couples, aligning it with existing benefits for heterosexual partners.
OTO Launches Fertility Diagnostic Wearable featuring Cira, new patented biometric and AI-powered wrist-worn biosensor technology designed to decode reproductive preparedness with precision and personalized insights.
President Trump’s IVF initiative announces most-favored-nation pricing with EMD Serono to slash fertility drug costs and launches TrumpRx.gov access, alongside new guidance enabling employer fertility benefits. FDA will expedite Pergoveris review, aiming to improve affordability, access, and outcomes for Americans seeking IVF treatment.
Infertility Treatment Drugs from Merck have enabled the births of 6 million babies globally, with 50% of conceived individuals tied to its therapies.
Aksigen IVF has launched an innovative Immersive IVF Knowledge Centre in Mumbai, dedicated to advancing fertility education by demystifying complex IVF science and empowering patients to make informed, confident decisions about their family planning journey.
Hana Health from DSS Imagetech and Overture Life collaborate to bring irst Automated Egg-Freezing Technology in India, giving couples access to a technology that reduces variability at the critical egg-freezing stage for successful pregnancy and healthy child birth.
According to a landmark large-scale IVF trial, using natural ovulation for frozen embryo transfers achieves matching birth rates to standard hormone cycles, offering a safer alternative for women.
